Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

Our lead investigational drug candidate is relugolix, a small molecule, GnRH receptor antagonist. We have three clinical programs for relugolix which consisted of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO). We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential treatment for women undergoing assisted reproduction, such as in vitro fertilization (IVF).

Over time, we intend to expand our development pipeline to include other potential treatments for women's health and prostate cancer.

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
September 29, 2020
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
September 23, 2020
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
September 14, 2020
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
Events

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA